Paragon BioTeck has received FDA approval of its phenylephrine hydrochloride ophthalmic solution, USP 2.5% and 10%, to dilate the pupil.
Portland-Paragon BioTeck has received FDA approval of its phenylephrine hydrochloride ophthalmic solution, USP 2.5% and 10%, to dilate the pupil.
According to the company, there is no longer a need to continue using unapproved versions of the solution as Paragon’s newly FDA-approved alpha-1 adrenergic receptor agonist is readily available through Bausch + Lomb.
“Paragon is committed to working proactively with the FDA in an effort to prevent disrupting supply of this and future drugs that play a vital role in managing ocular health,” said Patrick H. Witham, president and chief executive officer of Paragon.
For more articles in this issue of Ophthalmology Times eReport, click here.
